Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × INDUSTRY × Radiation Dose Hypofractionation × Clear all

Phase

Status

Sponsor Class

OTHER 21 UNKNOWN 2 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Advanced Cancer 1

Interventions

Paclitaxel 423 Carboplatin 373 Gemcitabine 345 Docetaxel 340 Cisplatin 311 Bevacizumab 299 pembrolizumab 283 Nivolumab 221 Pemetrexed 206 Capecitabine 200 Fluorouracil 181 Rituximab 177 Dexamethasone 177 Trastuzumab 167 Cyclophosphamide 163 Oxaliplatin 144 Erlotinib Hydrochloride 131 Prednisone 130 atezolizumab 128 Ipilimumab 125 Cetuximab 123 Irinotecan 122 Leucovorin 116 Doxorubicin 116 Bortezomib 105 Sorafenib 101 Sunitinib 95 Lenalidomide 95 Radiotherapy 82 Everolimus 82

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02383212 2020-01-27

Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies

Regeneron Pharmaceuticals

Phase 1 Completed

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡